Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05421988
Other study ID # NIIH20220324
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 20, 2022
Est. completion date July 20, 2027

Study information

Verified date April 2024
Source Soul Medicine Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Serious medical diagnosis frequently induce fear focused on specific anticipations or generalized anxiety, along with uncertainty, insecurity, and disorientation. Other emotions such as anger, depression, hopelessness, shame, or grief may also become involved following a serious diagnosis. The adverse impact of stress on health and immune function is well-established, as well as its link to depression and anxiety. Emotional Freedom Techniques (EFT) has demonstrated efficacy in treating anxiety, depression, and PTSD. This study tests its effectiveness in reducing negative emotional symptoms in general, and fear of recurrence in particular, among individuals previously diagnosed with melanoma and currently in remission.


Description:

Serious medical diagnosis frequently induce fear focused on specific anticipations or generalized anxiety, along with uncertainty, insecurity, and disorientation. Other emotions such as anger, depression, hopelessness, shame, or grief may also become involved following a serious diagnosis. The adverse impact of stress on health and immune function is well-established, as well as its link to depression and anxiety. Emotional Freedom Techniques (EFT) has demonstrated efficacy in treating anxiety, depression, and PTSD. This study tests its effectiveness in reducing negative emotional symptoms in general, and fear of recurrence in particular, among individuals previously diagnosed with melanoma and currently in remission. Specifically, the study aims: 1. To assess the effect of instruction and practice of EFT on illness perception, fear of cancer recurrence, and wellbeing. 2. To assess whether the social support provided by EFT instruction in a group setting makes this efficient mode of implementation non-inferior or even beneficial in comparison to personal instruction. 3. To describe the emotions related to life events reported by patients in connection with the appearance and location of melanoma.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 57
Est. completion date July 20, 2027
Est. primary completion date July 20, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Melanoma diagnosis over six months prior to the study; confirmed by clinical, dermoscopic examination and pathology results Exclusion Criteria: - In active treatment for melanoma - schizophrenia - epilepsy - other malignant disease

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Emotional Freedom Techniques (EFT)
EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.

Locations

Country Name City State
Israel The School Of Social Work Tel Aviv University Tel Aviv

Sponsors (2)

Lead Sponsor Collaborator
Soul Medicine Institute Tel Aviv University

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Illness perception Change in score on Revised Illness Perception Questionnaire (IPQ-R) Pre intervention, post 4 week intervention, and 3 month follow-up
Primary Perception of recurrence Change of perceived recurrence risk on a Likert scale Pre intervention, post 4 week intervention, and 3 month follow-up
Secondary Other physical symptoms Change in patient's self-report of somatization, pain, and other symptoms on a Likert scale Pre intervention, post 4 week intervention, and 3 month follow-up
Secondary Depression Change in depressive symptoms on the Positive and Negative Affect Schedule (PANAS) Pre intervention, post 4 week intervention, and 3 month follow-up
Secondary Anxiety Change in anxiety symptoms on the Positive and Negative Affect Schedule (PANAS) Pre intervention, post 4 week intervention, and 3 month follow-up
Secondary Patient's self-report of quality of life Change in quality of life scores on the Quality of Life Scale (QOLS) Pre intervention, post 4 week intervention, and 3 month follow-up
Secondary Wellbeing Change in score on The Well-being Numerical Rating Scales (WB-NRSs). Pre intervention, post 4 week intervention, and 3 month follow-up
See also
  Status Clinical Trial Phase
Completed NCT04062032 - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma Phase 2
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Completed NCT00962845 - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery Early Phase 1
Completed NCT00324623 - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma Phase 1
Completed NCT00096382 - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00104845 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 1
Completed NCT00072124 - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Phase 3
Completed NCT00089193 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 2
Completed NCT00072085 - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma Phase 2
Active, not recruiting NCT00039234 - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Phase 3
Completed NCT00042783 - Vaccine Therapy in Treating Patients With Stage IV Melanoma Phase 2
Completed NCT00049010 - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma N/A
Completed NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer Phase 1
Completed NCT00020358 - Vaccine Therapy in Treating Patients With Melanoma Phase 2
Completed NCT00005610 - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Phase 2
Completed NCT00006385 - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Withdrawn NCT00006126 - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery Phase 1